Omega-3 Supplementation in HIV Patients With Therapeutic Lifestyle Change Diet.

NCT ID: NCT02537236

Last Updated: 2015-09-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The positive patients to the Human Immunodeficiency Virus (HIV) with Highly Active Antiretroviral Therapy (HAART) present multiple alterations in their corporal composition and dyslipidemia, wich increase the cardiovascular risk.

The investigators evaluated the efficiency of the combination of fish oil omega 3 fatty acids to different doses with the Therapeutic Lifestyle Changes (TLC) diet of the National Cholesterol Education Program on the profile of lipids and the corporal weight in patients with HIV treated with HAART.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The infection by Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS), is a chronic condition transmissible and progressive type of viral cause, in which a link is very different between host and virus, which ultimately influences the appearance of opportunistic morbid processes or rare tumors, or both1.

With a prevalence of 3 cases for every 1000 people from 15 to 49 years, Mexico ranks 16th place in the prevalence of HIV/AIDS in adults in Latin America2.

The state of Jalisco, México, occupies the fourth place in terms of positive cases of HIV-AIDS, in this same plane, the municipalities of Guadalajara, Zapopan, Tlaquepaque and Puerto Vallarta in Jalisco, represent the main populations with the highest number of positive cases by HIV-AIDS.

The HIV positive individuals with Highly Active Antiretroviral Therapy (HAART) or without treatment are facing numerous challenges in terms of management of their health; some of the most disturbing changes are visible in the shape and appearance of the body. In most cases this anatomical changes come accompanied by alterations in biochemical indicators: lipid levels (cholesterol and triglycerides) and insulin resistance4.These adverse effects may have important clinical implications, such as severe lactic acidosis, coronary artery disease and acute pancreatitis5.

In patients with HIV and HAART has published an incidence of hypercholesterolemia and hypertriglyceridemia between 5 and 90% depending on the series, although the true incidence is yet to be determined6. Pharmacological interventions with statins or fibrates in patients infected with HIV are limited partially due to the drug interactions and increase in the frequency of adverse effects7.

Therefore, it is necessary to investigate new alternatives for the management of dyslipidemia in patients infected with HIV with HAART through changes in diet and supplements of fish oil omega 3 fatty acids.

Methods Patients: The investigators enrolled 100 Patients positive to Human Immunodeficiency Virus or Acquired Immunodeficiency Syndrome, and had been receiving ≥2 Highly Active Antiretroviral Therapy, and with diagnostic of dislipidemia according the Mexican Official Standard Norms of 2002, for the prevention, treatment and control of dyslipidemias8.

All the patients were active in the SMART database from HIV/AIDS department of the Civil Hospital in Guadalajara "Fray Antonio Alcalde". Patients were excluded for intolerance or allergy to fish, patients that use or have used in the last 6 weeks supplements or drugs that modify lipids.

Study design During the period from January 2010 to July 2011, was carried out the study with the authorization of the ethics committee of the Civil Hospital in Guadalajara "Fray Antonio Alcalde".

Our subjects were assigned to 5 intervention groups: Groups one= 20 subjects received Therapeutic Lifestyle Changes diet more 1.05 grams of Fatty Acid omega 3. Groups two= 20 subjects received conventional diet more 1.05 grams of Fatty Acid omega three. Groups 3=20 subjects received Therapeutic Lifestyle Changes diet more 2.10 grams of Fatty Acid omega 3. Groups four=20 subjects received conventional diet more 2.10 grams of Fatty Acid omega 3. Groups five= 20 subjects, control group received conventional diet.

The subject assigned to group one and three with TLC diet, received advice from the nutritionist in week 4 and 12 to encourage the consumption of the capsules of omega 3 fatty acids, in addition offered general recommendations to consume dietary fiber and fluids.

The subject assigned to groups two and four with conventional diet, received advice from the nutritionist in the week 4 and 12 to encourage the consumption of the capsules of omega 3 fatty acids without the assistance of special diet.

The requirements of energy and macronutrients were identified in the patients of group one and three.

None of the subjects received advice on the physical activity that could perform.

Statistical analysis

The main objective of this study was to compare the changes in fasting levels of triglycerides (TG), total cholesterol (TC), high density cholesterol (HD-C), low density cholesterol (LD-C), very low density cholesterol (VLD-C), the body weight and body mass index (BMI) against the week 4 and 12.

The safety and tolerability of the study medication were also secondary outcomes.

Statistical analysis was carried out starting with the Kolmogorov-Smirnov test to identify the distribution of variables, then identify the type of distribution of each variable, is continuous with the descriptive statistical analysis for variables with abnormal distribution -non-parametric, with measures of central tendency and dispersion as: the median distance and interquartiles and variables with normal distribution - parametric- :the mean and standard deviation.

Inferential analysis to the intra-group used the Wilcoxon test and Friedman. For the inferential analysis between groups was implemented in the variables of non-normal distribution, the Kruskal-Wallis test; and for variables with normal distribution was used the one-way ANOVA test. Differences were considered statistically significant when the p value was \<0.05 .

The data were processed using the statistical package No.18.0 and are presented in tables and graphics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Immunodeficiency Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group one

20 subjects received Therapeutic Lifestyle Changes diet more 1.05 grams of fish oil omega 3 fatty acids

Group Type EXPERIMENTAL

Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.

Intervention Type DIETARY_SUPPLEMENT

Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.

Group two

20 subjects received conventional diet more 1.05 grams of fish oil omega 3 fatty acids

Group Type ACTIVE_COMPARATOR

Omega-3 fatty acids

Intervention Type DIETARY_SUPPLEMENT

Omega-3 fatty acid supplementation with fish oil.

Group three

20 subjects received Therapeutic Lifestyle Changes diet more 2.10 grams of fish oil omega 3 fatty acids.

Group Type EXPERIMENTAL

Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.

Intervention Type DIETARY_SUPPLEMENT

Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.

Group four

20 subjects received conventional diet more 2.10 grams of fish oil omega 3 fatty acids

Group Type ACTIVE_COMPARATOR

Omega-3 fatty acids

Intervention Type DIETARY_SUPPLEMENT

Omega-3 fatty acid supplementation with fish oil.

Group five

20 subjects, control group received conventional diet.

Group Type PLACEBO_COMPARATOR

TLC nutritional intervention

Intervention Type BEHAVIORAL

nutritional orientation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omega-3 fatty acids

Omega-3 fatty acid supplementation with fish oil.

Intervention Type DIETARY_SUPPLEMENT

TLC nutritional intervention

nutritional orientation.

Intervention Type BEHAVIORAL

Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.

Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

eicosapentaenoic acid docosahexaenoic acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients positive to Human Immunodeficiency Virus or Acquired Immunodeficiency Syndrome
* Patients older than 18 years positive to HIV/AIDS with HAART
* Patients who agreed to sign consent under written information
* Patients that had some type of dyslipidemia according the Mexican Norms of 2002.

Exclusion Criteria

* Patient with mouth non-permeable
* Patients with intolerance or allergy to fish oil
* Patient record in the database SMART but inactive.
* Patients who use or have used in the last 6 weeks food supplements that modify lipids.
* Patient who have not attended two of the four set appointments for valuation.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Civil de Guadalajara

OTHER

Sponsor Role collaborator

Instituto Mexicano del Seguro Social

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alejandro Gonzalez-Ojeda

MD., Ph.D., F.A.C.S.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alejandro González-Ojeda, MD. PhD. F.A.C.S.

Role: STUDY_DIRECTOR

Instituto Mexicano del Seguro Social

References

Explore related publications, articles, or registry entries linked to this study.

Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998 May 7;12(7):F51-8. doi: 10.1097/00002030-199807000-00003.

Reference Type BACKGROUND
PMID: 9619798 (View on PubMed)

Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000 Jan 1;23(1):35-43. doi: 10.1097/00126334-200001010-00005.

Reference Type BACKGROUND
PMID: 10708054 (View on PubMed)

Wohl DA, Tien HC, Busby M, Cunningham C, Macintosh B, Napravnik S, Danan E, Donovan K, Hossenipour M, Simpson RJ Jr. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005 Nov 15;41(10):1498-504. doi: 10.1086/497273. Epub 2005 Oct 11.

Reference Type BACKGROUND
PMID: 16231263 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

omega-3-HIV/2009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Omega-3 Supplementation and Behavior Problems
NCT02334098 COMPLETED PHASE2/PHASE3
Omega-3 Fatty Acids for Autism Treatment
NCT00786799 COMPLETED PHASE2